Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Change in Receivables (2016 - 2026)

Champions Oncology has reported Change in Receivables over the past 14 years, most recently at $498000.0 for Q1 2026.

  • For Q1 2026, Change in Receivables fell 90.55% year-over-year to $498000.0; the TTM value through Jan 2026 reached -$3.7 million, down 147.65%, while the annual FY2025 figure was $1.4 million, 27.88% down from the prior year.
  • Change in Receivables for Q1 2026 was $498000.0 at Champions Oncology, down from $2.1 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $5.3 million in Q1 2025 and troughed at -$4.5 million in Q2 2025.
  • A 5-year average of $260764.7 and a median of $250000.0 in 2024 define the central range for Change in Receivables.
  • Biggest five-year swings in Change in Receivables: plummeted 353.49% in 2023 and later skyrocketed 2500.0% in 2024.
  • Year by year, Change in Receivables stood at -$276000.0 in 2022, then crashed by 317.39% to -$1.2 million in 2023, then skyrocketed by 206.68% to $1.2 million in 2024, then skyrocketed by 69.08% to $2.1 million in 2025, then tumbled by 76.03% to $498000.0 in 2026.
  • Business Quant data shows Change in Receivables for CSBR at $498000.0 in Q1 2026, $2.1 million in Q4 2025, and -$1.8 million in Q3 2025.